Mesoblast Limited

(NASDAQ:MESO)

Latest On Mesoblast Limited (MESO):

Date/Time Type Description Signal Details
2023-05-26 06:19 ESTNewsMesoblast Limited (MESO) Q3 2023 Earnings Call TranscriptN/A
2023-05-26 06:19 ESTNewsMesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18MN/A
2023-05-04 20:51 ESTNewsMesoblast Has A Strong Upside PotentialN/A
2023-03-08 20:50 ESTNewsMesoblast stock surges ~10% on getting FDA review of graft versus host disease therapyN/A
2023-03-02 11:37 ESTNewsMesoblast Limited. (MESO) Q2 2023 Earnings Call TranscriptN/A
2023-02-28 14:47 ESTNewsMesoblast Limited 2023 Q2 - Results - Earnings Call PresentationN/A
2022-12-23 19:10 ESTNewsMesoblast and Oaktree extend availability of undrawn facilityN/A
2022-12-06 13:18 ESTNewsMesoblast stock falls 10% as Jefferies cuts rating to HoldN/A
2022-11-24 00:38 ESTNewsMesoblast Limited (MESO) Q1 2023 Earnings Call TranscriptN/A
2022-11-23 07:29 ESTNewsMesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82MN/A
2022-10-31 12:34 ESTNewsMesoblast reports operational and financial highlights for Q3N/A
2022-08-31 07:31 ESTNewsMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2022-08-31 07:31 ESTNewsMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptN/A
2022-08-31 07:31 ESTNewsMesoblast GAAP EPS of -$0.14, revenue of $10.21MN/A
2022-06-01 09:26 ESTNewsMesoblast GAAP EPS of -$0.03, revenue of $2MN/A
2022-02-02 13:18 ESTNewsNew medical chief at MesoblastN/A
2022-01-12 16:28 ESTNewsMesoblast’s rexlemestrocel-L results in durable pain reduction in degenerative disc diseaseN/A
2021-12-31 16:22 ESTNewsMesoblast to provide new data to FDA to support remestemcel-L BLA resubmissionN/A
2021-12-16 20:12 ESTNewsFDA’s OTAT in agreement pain reduction as primary endpoint in Mesoblast's Phase 3 programN/A
2021-12-14 07:58 ESTNewsMesoblast falls 8% after Novartis terminates deal prior to closingN/A
2021-12-06 08:59 ESTNewsMesoblast's rexlemestrocel-L shows treatment benefit in cardiovascular events in heart patientsN/A
2021-11-24 11:49 ESTNewsMesoblast EPS beats by $0.10, beats on revenueN/A
2021-11-22 16:32 ESTNewsMesoblast and Oaktree Capital refinance senior debt facilityN/A
2021-11-15 18:27 ESTNewsMesoblast's rexlemestrocel-l shows reduction in cardiovascular mortality, heart attacks and strokesN/A
2021-08-31 00:59 ESTNewsMesoblast EPS beats by $0.38N/A
2021-07-22 15:51 ESTNewsMesoblast reports FQ3 resultsN/A
2021-07-22 15:48 ESTNewsMesoblast provides update on rexlemestrocel-L in development for low back painN/A
2021-07-22 15:47 ESTNewsMesoblast reports respiratory function results of COVID-19 ARDS trialN/A
2021-07-22 15:47 ESTNewsMesoblast presents data showing mortality reduction of COVID-19 therapyN/A
2021-05-01 01:30 ESTNewsMESO, MOTS and SALM among premarket gainersN/A
2021-04-30 03:28 ESTNewsMesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDSN/A
2021-04-08 03:05 ESTNewsMaxim upgrades Mesoblast to buy, sets $18 price targetN/A
2021-03-17 15:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.5 to $13.7.Neutral
2021-03-16 23:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.5.Neutral
2021-03-03 00:44 ESTNewsMesoblast announces a private placement of $110 millionN/A
2021-03-01 01:44 ESTEarnings EstimateAn EPS average of $0.03 is estimated for the quarter ending on March 31, 2021.Buy
2021-02-28 05:42 ESTFinancialsCompany financials have been released.Neutral
2021-02-17 14:54 ESTNewsMesoblast gains as remestemcel-l shows positive action in MIS-C post COVID-19N/A
2021-02-15 13:38 ESTAnalyst RatingThe Analyst Target Price has increased from $14.29 to $14.96.Buy
2021-02-12 12:18 ESTNewsMesoblast announces data from Phase 3 study in chronic back painN/A
2021-01-29 11:38 ESTNewsMesoblast issues FQ2 operational and financial updateN/A
2021-01-27 14:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.29.Neutral
2021-01-19 22:20 ESTNewsMesoblast's Time May Be UpN/A
2021-01-11 12:34 ESTNewsMesoblast's rexlemestrocel-l reduces heart attacks, strokesN/A
2020-12-25 10:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.45 to $14.96.Neutral
2020-12-24 16:56 ESTNewsMesoblast: The Future Looks BleakN/A
2020-12-24 02:40 ESTAnalyst RatingThe Analyst Target Price has increased from $14.96 to $16.45.Buy
2020-12-23 18:45 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.39 to $14.96.Neutral
2020-12-20 22:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.82 to $15.39.Neutral
2020-12-18 05:21 ESTNewsMesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19N/A

About Mesoblast Limited (MESO):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

MESO Quotes by TradingView

See Advanced Chart

General

  • Name Mesoblast Limited
  • Symbol MESO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 102
  • Fiscal Year EndJune
  • IPO Date2015-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.mesoblast.com
View More

Valuation

  • Forward PE 454.55
  • Price/Sales (Trailing 12 Mt.) 62.46
  • Price/Book (Most Recent Quarter) 2.28
  • Enterprise Value Revenue 70.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.29
  • Next Year EPS Estimate $0.17
  • Operating Margin -682%
  • Return on Assets -10%
  • Return on Equity -19%
  • Revenue 16.45 million
  • Earnings Per Share -$0.91
  • Revenue Per Share $0.15
  • Gross Profit 6.85 million
  • Quarterly Earnings Growth 1.6%
View More

Highlights

  • Market Capitalization 1.26 billion
  • EBITDA -78815000
  • Analyst Target Price $13.7
  • Book Value Per Share $4.42
View More

Share Statistics

  • Shares Outstanding 129.62 million
  • Shares Float 101.69 million
  • % Held by Insiders <1%
  • % Held by Institutions 2.87%
  • Shares Short 1.88 million
  • Shares Short Prior Month 2.82 million
  • Short Ratio 4.29
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.71
  • 52 Week High $21.28
  • 52 Week Low $3.12
  • 50 Day Moving Average 9.64
  • 200 Day Moving Average 12.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Mesoblast Limited (MESO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Mesoblast Limited (MESO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-26$N/A-$0.22-$0.15-43.61%
2020-09-302020-11-19$N/A-$0.21-$0.2619.04%
2020-06-302020-08-26$N/A-$0.30-$0.21-42.52%
2020-03-312020-05-27$12.08 million-$0.14-$0.1612.62%
2019-12-312020-02-26$2.21 million-$0.23-$0.13-71.64%
2019-09-302019-11-25$16.87 million-$0.06-$0.1970.27%
2019-06-302019-08-29$1.25 million-$0.21-$0.2724.04%
2019-03-312019-05-30$1.25 million-$0.25-$0.263.85%
2018-12-312019-02-20$1.87 million-$0.25-$0.23-8.7%
2018-09-302018-11-15$11.64 million-$0.20-$0.2311.52%
2018-06-302018-08-29$1.7 million-$0.22-$0.232.19%
2018-03-312018-05-30$1.07 million-$0.22-$0.22-1.59%
2017-12-312018-02-27$13.28 million$0.15-$0.20172.03%
2017-09-302017-11-14$1.11 million-$0.08-$0.2467.21%
2017-06-302017-08-29$473000-$0.32-$0.21-50.59%
2017-03-312017-05-24$820000-$0.12-$0.1935.26%
2016-12-312017-02-26$433000-$0.26-$0.20-34.92%
2016-09-302016-11-14$218000-$0.05-$0.2175.05%
2016-06-302016-08-24$26.62 million$0.64-$0.20423.54%
2016-03-312016-05-09$3.85 million-$0.04-$0.1263.7%
2015-12-312016-02-16$3.75 million-$0.31-$0.17-80.75%
2015-09-302015-12-16$7.25 million-$0.19

Mesoblast Limited (MESO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Research Development N/A N/A N/A N/A 14.38 million
Income Before Tax N/A N/A N/A N/A -17.22 million
Selling General Administrative N/A N/A N/A N/A 5.73 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A N/A N/A -12.54 million
Operating Income N/A N/A N/A N/A -15.64 million
Income Tax Expense 74000 -730000 -3.26 million -3.26 million -1.96 million
Total Revenue N/A N/A N/A N/A 12.08 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A 2.04 million
Net Income From Continuing Operations N/A N/A N/A N/A -15.26 million
Net Income Applicable to Common Shares -25.69 million -24.54 million -32.61 million -32.61 million -15.26 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020 Jan 31 2020
Investments -81000 -1.87 million -1.87 million -693000 -693000
Change to Liabilities N/A N/A 6.2 million 403000 403000
Total Cash Flow from Investing Activities N/A N/A -1.87 million -693000 -693000
Net Borrowings N/A N/A -406000 -524000 -524000
Total Cash Flow from Financial Activities 6.54 million 88.92 million 88.92 million -65000 -65000
Change to Operating Activities N/A N/A 2.54 million -6.51 million -6.51 million
Change in Cash N/A 67.47 million 67.47 million -20.65 million -20.65 million
Total Cash from Operating Activities N/A N/A -19.58 million -19.9 million -19.9 million
Depreciation N/A N/A N/A 946000 946000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A 64000 64000
Other Cash Flow from Financing Activities N/A N/A -4.07 million -47000 -47000
Change to Net Income N/A N/A 1.84 million 463000 463000
Capital Expenditures 81000 841000 841000 693000 693000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Total Liabailities N/A N/A N/A N/A 177.98 million
Total Stockholder Equity N/A N/A N/A N/A 487.81 million
Other Current Liabilities 18.31 million 22.22 million N/A N/A N/A
Total Assets N/A N/A N/A N/A 665.79 million
Common Stock 1.07 billion 1.06 billion 1.05 billion N/A 960.45 million
Other Current Assets N/A N/A N/A 1.05 billion N/A
Retained Earnings -598.99 million -573.3 million -548.76 million -548.76 million -516.15 million
Other Liabilities 21.94 million 23.22 million 30.79 million 30.79 million 35.58 million
Other Assets 3.21 million 3.33 million 3.31 million 3.31 million 3.24 million
Cash N/A N/A N/A N/A 60.08 million
Total Current Liabilities 91.04 million 87.7 million N/A N/A 76.69 million
Other Stockholder Equity 52.19 million 48.8 million 46.63 million 46.63 million 43.51 million
Property, Plant & Equipment 10.41 million 10.33 million 10.27 million 10.27 million 9.44 million
Total Current Assets 90.46 million 115.74 million N/A N/A 69.39 million
Long Term Investments N/A N/A N/A N/A 1.77 million
Net Tangible Assets -62.6 million -42.71 million -32.28 million -32.28 million -94.13 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A 59.95 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable 28.61 million 27.6 million N/A N/A 19.48 million

Mesoblast Limited (MESO) Chart:

Mesoblast Limited (MESO) News:

Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mesoblast Limited (MESO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-07-1830CALL0 01200.45TRUE00
2025-07-1850CALL0 0284.36TRUE00
2025-07-1860CALL0 0569.27TRUE00
2025-07-1873.65CALL0 60111.05TRUE00
2025-07-1883.9CALL0 60197.69TRUE00
2025-07-1892.01CALL0 7589.83TRUE00
2025-07-18101.2CALL12 48273.93TRUE1.20
2025-07-18110.7CALL0 4792.49FALSE00
2025-07-18120.42CALL0 64781.75FALSE00
2025-07-18130.25CALL0 136117.36FALSE00
2025-07-18140.18CALL0 96132.85FALSE00
2025-07-18150.15CALL10 2493104.31FALSE0.050.5
2025-07-18160.17CALL0 1195131.67FALSE00
2025-07-18170CALL0 101365.61FALSE00
2025-07-18180CALL0 170404.77FALSE00
2025-07-18190CALL0 506418.91FALSE00
2025-07-18200.1CALL0 5586162.35FALSE00
2025-07-18210CALL0 18444.15FALSE00
2025-07-18220CALL0 81455.51FALSE00
2025-07-18230.15CALL0 108466.15FALSE00
2025-07-18240.1CALL0 5325181.14FALSE00
2025-07-18250CALL0 29268.83FALSE00
2025-07-18260CALL0 7494.57FALSE00
2025-07-18270CALL0 155503.07FALSE00
2025-07-18280CALL0 1511.15FALSE00
2025-07-18290CALL0 0518.86FALSE00
2025-07-18300CALL0 45526.22FALSE00
2025-07-18310CALL0 1533.26FALSE00
2025-07-18320CALL0 8540.01FALSE00
2025-07-18330CALL0 4546.49FALSE00
2025-07-18340CALL0 2552.72FALSE00
2025-07-18350CALL0 2558.72FALSE00
2025-07-1830PUT0 01374.78FALSE00
2025-07-1850PUT0 2753.96FALSE00
2025-07-1860PUT0 8616.83FALSE00
2025-07-1870PUT0 9193.44FALSE00
2025-07-1880.22PUT0 8168.82FALSE00
2025-07-1890.4PUT0 1793.14FALSE00
2025-07-18100.9PUT0 49481.95FALSE00
2025-07-18111.45PUT0 125111.65TRUE00
2025-07-18121.36PUT0 38150.84TRUE00
2025-07-18132.79PUT0 41156.36TRUE00
2025-07-18144PUT0 4193.4TRUE00
2025-07-18153.37PUT0 113599.81TRUE00
2025-07-18164PUT0 25123.71TRUE00
2025-07-18174.8PUT0 23219.13TRUE00
2025-07-18180PUT0 589175.08TRUE00
2025-07-18190PUT0 0252.4TRUE00
2025-07-18209.55PUT0 33205.94TRUE00
2025-07-18210PUT0 10199.64TRUE00
2025-07-18220PUT0 0268.36TRUE00
2025-07-18230PUT0 0278.18TRUE00
2025-07-18240PUT0 0306.2TRUE00
2025-07-18250PUT0 3321.17TRUE00
2025-07-18260PUT0 0290.88TRUE00
2025-07-18270PUT0 0331.64TRUE00
2025-07-18280PUT0 0333TRUE00
2025-07-18290PUT0 0263.02TRUE00
2025-07-18300PUT0 0365.99TRUE00
2025-07-18310PUT0 0326.49TRUE00
2025-07-18320PUT0 0366.8TRUE00
2025-07-18330PUT0 0373TRUE00
2025-07-18340PUT0 0365.8TRUE00
2025-07-18350PUT0 0286.55TRUE00
2025-08-1550CALL0 0416.6TRUE00
2025-08-1560CALL0 0127.91TRUE00
2025-08-1570CALL0 091.16TRUE00
2025-08-1580CALL0 074.85TRUE00
2025-08-1590CALL0 069.28TRUE00
2025-08-15100CALL0 0125.16TRUE00
2025-08-15112.22CALL0 9106.36FALSE00
2025-08-15120.73CALL0 2174.99FALSE00
2025-08-15130CALL0 0153.91FALSE00
2025-08-15140CALL0 0147.42FALSE00
2025-08-15150CALL0 0120.46FALSE00
2025-08-15160CALL0 0151.4FALSE00
2025-08-15170CALL0 0136.43FALSE00
2025-08-15200CALL0 0157.8FALSE00
2025-08-1550PUT0 0501.56FALSE00
2025-08-1560PUT0 0410.43FALSE00
2025-08-1570PUT0 0331.11FALSE00
2025-08-1580.39PUT0 5151.53FALSE00
2025-08-1590PUT0 0167.48FALSE00
2025-08-15100.95PUT1 186.23FALSE0.950
2025-08-15110PUT0 056.19TRUE00
2025-08-15120PUT0 0104.55TRUE00
2025-08-15130PUT0 0119.93TRUE00
2025-08-15140PUT0 0108.74TRUE00
2025-08-15150PUT0 083.4TRUE00
2025-08-15160PUT0 0122.2TRUE00
2025-08-15170PUT0 0119.89TRUE00
2025-08-15200PUT0 0166.84TRUE00
2025-10-1730CALL0 0402.75TRUE00
2025-10-1756.8CALL0 121275.67TRUE00
2025-10-1764.8CALL0 24249.17TRUE00
2025-10-1770CALL0 1554.07TRUE00
2025-10-1784.56CALL0 11982.14TRUE00
2025-10-1790CALL0 382.94TRUE00
2025-10-17102.45CALL30 59087.27TRUE0.120.05
2025-10-17112.05CALL20 24488.5FALSE2.050
2025-10-17121.6CALL1 197984.58FALSE0.050.03
2025-10-17131.4CALL2 61988.61FALSE1.40
2025-10-17141.1CALL20 46786.22FALSE1.10
2025-10-17151CALL56 41790.74FALSE0.10.11
2025-10-17160.85CALL4 63591.63FALSE0.020.02
2025-10-17170.7CALL0 19298.61FALSE00
2025-10-17180.65CALL1 95194.74FALSE0.050.08
2025-10-17191CALL0 188104.36FALSE00
2025-10-17200.48CALL0 5153117.38FALSE00
2025-10-17210.37CALL0 106142.82FALSE00
2025-10-17220CALL0 8120.46FALSE00
2025-10-17230CALL0 200119.16FALSE00
2025-10-17250CALL0 3123.93FALSE00
2025-10-17300CALL0 3128.05FALSE00
2025-10-1730PUT0 0614.75FALSE00
2025-10-1750PUT0 0300.77FALSE00
2025-10-1760.35PUT0 275141.1FALSE00
2025-10-1770PUT0 0140.03FALSE00
2025-10-1780PUT0 25136.63FALSE00
2025-10-1790PUT0 2118.01FALSE00
2025-10-17102PUT0 22580.44FALSE00
2025-10-17111.75PUT0 1492.13TRUE00
2025-10-17122.3PUT0 178785.32TRUE00
2025-10-17134.2PUT0 1695.99TRUE00
2025-10-17143.55PUT0 1197.31TRUE00
2025-10-17150PUT0 206102.42TRUE00
2025-10-17160PUT0 0108.59TRUE00
2025-10-17170PUT0 0109.26TRUE00
2025-10-17180PUT0 0111.32TRUE00
2025-10-17190PUT0 0109.98TRUE00
2025-10-17209.9PUT0 33113.01TRUE00
2025-10-17210PUT0 0103.61TRUE00
2025-10-17220PUT0 0111.6TRUE00
2025-10-17230PUT0 0122.26TRUE00
2025-10-17250PUT0 0127.69TRUE00
2025-10-17300PUT0 0148.81TRUE00
2026-01-160.50CALL0 200TRUE00
2026-01-1610CALL0 100TRUE00
2026-01-161.50CALL0 00TRUE00
2026-01-1620CALL0 1000TRUE00
2026-01-162.50CALL0 12610TRUE00
2026-01-1630CALL0 0132.91TRUE00
2026-01-1640CALL0 100TRUE00
2026-01-1650CALL0 055.22TRUE00
2026-01-1664.63CALL0 80160.75TRUE00
2026-01-1676.9CALL0 2779.3TRUE00
2026-01-1684.83CALL0 297.68TRUE00
2026-01-1690CALL0 077.98TRUE00
2026-01-16102.73CALL0 10375.33TRUE00
2026-01-16112.3CALL0 078.17FALSE00
2026-01-16122.35CALL40 36385.25FALSE2.350
2026-01-16130CALL0 069.5FALSE00
2026-01-16141.9CALL0 2783.72FALSE00
2026-01-16151.6CALL40 31085.95FALSE1.60
2026-01-16162.3CALL0 184.08FALSE00
2026-01-16172.1CALL0 2100.84FALSE00
2026-01-16181.65CALL0 1590.35FALSE00
2026-01-16201CALL0 151135.4FALSE00
2026-01-160.50PUT0 0343.62FALSE00
2026-01-1610PUT0 0236.05FALSE00
2026-01-161.50PUT0 0189.92FALSE00
2026-01-1620PUT0 20161.02FALSE00
2026-01-162.50PUT0 0158.33FALSE00
2026-01-1630PUT0 0463.2FALSE00
2026-01-1640PUT0 0153.53FALSE00
2026-01-1650PUT0 0237.02FALSE00
2026-01-1660PUT0 0194.67FALSE00
2026-01-1670.8PUT0 3114.17FALSE00
2026-01-1681.4PUT0 7109.56FALSE00
2026-01-1691.9PUT0 2095.06FALSE00
2026-01-16102.4PUT20 595.03FALSE2.40
2026-01-16110PUT0 088.24TRUE00
2026-01-16120PUT0 090.74TRUE00
2026-01-16130PUT0 0100.4TRUE00
2026-01-16145.6PUT0 5123.8TRUE00
2026-01-16150PUT0 0109.13TRUE00
2026-01-16166.3PUT0 196.85TRUE00
2026-01-16170PUT0 097.98TRUE00
2026-01-16180PUT0 098.45TRUE00
2026-01-16200PUT0 0109.75TRUE00
2030-12-18100.2CALL456 3400TRUE-3.3-0.94
2030-12-18250PUT 0TRUE00

Latest MESO Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:55 PM EST100$2.64
Jun 13, 2022 7:57 PM EST186$2.66
Jun 13, 2022 7:57 PM EST14$2.66

Mesoblast Limited (MESO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000119312520019148/0001193125-20-019148-index.htm
2020-07-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1345099/000121390020018628/0001213900-20-018628-index.htm
2020-05-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1345099/000134509920000001/0001345099-20-000001-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000142284920000077/0001422849-20-000077-index.htm
2019-09-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034209/0001564590-19-034209-index.htm
2019-09-0920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034304/0001564590-19-034304-index.htm
2019-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034483/0001564590-19-034483-index.htm
2019-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036315/0001564590-19-036315-index.htm
2019-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036431/0001564590-19-036431-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036737/0001564590-19-036737-index.htm
2019-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019037256/0001564590-19-037256-index.htm
2019-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019039260/0001564590-19-039260-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019041204/0001564590-19-041204-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044600/0001564590-19-044600-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044601/0001564590-19-044601-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044825/0001564590-19-044825-index.htm
2019-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019045775/0001564590-19-045775-index.htm
2019-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019046754/0001564590-19-046754-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020000984/0001564590-20-000984-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020001658/0001564590-20-001658-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003090/0001564590-20-003090-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003512/0001564590-20-003512-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020004688/0001564590-20-004688-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020006501/0001564590-20-006501-index.htm
2020-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020007597/0001564590-20-007597-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020009861/0001564590-20-009861-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020011865/0001564590-20-011865-index.htm
2020-03-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020012613/0001564590-20-012613-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020014830/0001564590-20-014830-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020015584/0001564590-20-015584-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020016005/0001564590-20-016005-index.htm
2020-04-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020017344/0001564590-20-017344-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020018322/0001564590-20-018322-index.htm
2020-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020020611/0001564590-20-020611-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020022226/0001564590-20-022226-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020025586/0001564590-20-025586-index.htm
2020-05-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026055/0001564590-20-026055-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026914/0001564590-20-026914-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027408/0001564590-20-027408-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027410/0001564590-20-027410-index.htm
2020-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020028116/0001564590-20-028116-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020029698/0001564590-20-029698-index.htm
2020-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020030668/0001564590-20-030668-index.htm
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031863/0001564590-20-031863-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020032147/0001564590-20-032147-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020033456/0001564590-20-033456-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020035263/0001564590-20-035263-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020038657/0001564590-20-038657-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020039445/0001564590-20-039445-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020040358/0001564590-20-040358-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041082/0001564590-20-041082-index.htm
2020-08-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041869/0001564590-20-041869-index.htm
2020-09-0320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042401/0001564590-20-042401-index.htm
2020-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042407/0001564590-20-042407-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042713/0001564590-20-042713-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043641/0001564590-20-043641-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043751/0001564590-20-043751-index.htm
2020-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020045777/0001564590-20-045777-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020046432/0001564590-20-046432-index.htm
2020-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020047335/0001564590-20-047335-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020048488/0001564590-20-048488-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020049709/0001564590-20-049709-index.htm